- Investing Ideas
- U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.S. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
8
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
8 companies
AbbVie
Market Cap: US$397.4b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$224.77
7D
-0.08%
1Y
16.8%
Merck
Market Cap: US$294.1b
Operates as a healthcare company worldwide.
MRK
US$120.76
7D
0.4%
1Y
47.6%
Travere Therapeutics
Market Cap: US$4.3b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$48.91
7D
5.9%
1Y
227.4%
Mesa Laboratories
Market Cap: US$592.4m
Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
MLAB
US$107.35
7D
-1.6%
1Y
7.5%
Waters
Market Cap: US$35.7b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$359.74
7D
-4.4%
1Y
2.9%
BioLife Solutions
Market Cap: US$1.3b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$26.60
7D
-1.8%
1Y
14.2%
Sotera Health
Market Cap: US$4.6b
Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$16.39
7D
5.3%
1Y
39.5%
Repligen
Market Cap: US$7.4b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$133.33
7D
5.4%
1Y
1.5%